On Monday, Shares of VMware, Inc. (NYSE:VMW), lost -8.10% to $72.28. 17.85 million shares of the company were exchanged.
VMware, Inc. (VMW), a leader in cloud infrastructure and business mobility, announced preliminary financial results for the third quarter of 2015.
Revenues for the third quarter are expected to be $1.672 billion, an increase of 10% from the third quarter of 2014, or an increase of 14% in constant currency. “I’m pleased with our overall Q3 results, with total revenue expected to exceed the high end of our guidance range,” said Jonathan Chadwick, chief financial officer, chief operating officer and executive vice president, VMware.
License revenues for the third quarter are expected to be $681 million, an increase of 7% from the third quarter of 2014, or an increase of 11% in constant currency. GAAP operating margin for the third quarter is predictable to be 19.5%. Non-GAAP operating margin for the third quarter is predictable to be 31.5%.
VMware, Inc. provides virtualization infrastructure solutions in the United States and internationally. The company’s virtualization infrastructure solutions comprise a suite of products designed to deliver a software-defined data center (SDDC), run on industry-standard desktop computers and servers, and support a range of operating system and application environments, in addition to networking and storage infrastructures.
Shares of Johnson & Johnson (NYSE:JNJ), inclined 0.67% to $96.01, during its last trading session.
Johnson & Johnson (JNJ) declared the start of a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies. Trial recruitment is underway, and the first volunteers have received their initial vaccine dose. This is the first study conducted of Janssen’s Ebola prime-boost vaccine regimen in a West African country affected by the recent Ebola epidemic.
The new study, EBOVAC-Salone, will take place in Sierra Leone’s Kambia district, where some of the country’s most recent Ebola cases have been stated. The regimen being tested uses a combination of two vaccine components based on AdVac® technology from Crucell Holland B.V., one of the Janssen Pharmaceutical Companies, and MVA-BN® technology from Bavarian Nordic. Volunteers in the study will first be given the AdVac dose to prime their immune system, and then the MVA-BN dose two months later to boost their immune response, with the aim of potentially strengthening and optimizing the duration of the immunity.
Since announcing its commitment to combat Ebola in October 2014, Johnson & Johnson has mobilized noteworthy resources to advance the research and development of an Ebola vaccine regimen with the aim of addressing the urgent public health need of affected countries such as Sierra Leone. With this aim in mind, in 2015 Janssen developed partnerships and consortia with other companies and research institutions, secured funding from European and U.S. public authorities, and launched multiple Phase I and II studies in rapid succession across the U.S., Europe and Africa. Additionally, Janssen in partnership with Bavarian Nordic, rapidly scaled up production of the vaccine regimen to more than 800,000 regimens, with the capacity to produce a total of 2 million regimens as needed.
Johnson & Johnson, together with its auxiliaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices.
At the end of Monday’s trade, Shares of Penn West Petroleum Ltd (USA) (NYSE:PWE), declined -2.48% to $1.18, as the decline in oil prices drives some energy and related stocks into the red Monday.
It traded in a range of $1.10 and $1.21, exchanging hands with 4.56 million shares.
The stock is down -41.88% in this year through last close. In the trailing twelve months, gross profit margin was 56.50%.
Comments from OPEC are also assisting boost the energy sector recently, as the group sees demand for its oil in 2016 will be much higher than it formerly predictable, Reuters added.
However, OPEC still has no plans to cut its production rate and the group pumped 31.57 million bpd in September, up 110,000 bpd from August, Reuters noted.
Penn West Petroleum Ltd. explores for, develops, and produces oil and natural gas properties in western Canada. The company’s properties are located in Alberta, British Columbia, Saskatchewan, Manitoba, and the Northwest Territories, Canada; and Wyoming, the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
